臨床外科79巻7号

2024年07月発行

特集 外科医が知っておくべき 肝胆膵腫瘍に対する薬物療法 胆道・膵臓

神経内分泌がんに対する薬物療法の現状と治療戦略

著者： 小林規俊¹

所属機関： ¹横浜市立大学大学院がん総合医科学

ページ範囲：P.791 - P.797

【ポイント】
◆神経内分泌がん（NEC）は，低分化，高悪性度のがんであり，神経内分泌腫瘍（NET）と異なった治療戦略が求められる．
◆局所進行NECに対する外科的治療の役割はいまだ明確ではなく，化学療法や放射線化学療法が重要な選択肢となる．
◆切除不能，遠隔転移を伴うNECに対する治療は，プラチナ系抗がん剤を基本とした，2剤併用療法である．

参考文献

1）Bosman FT, Carneiro F, Hruban RH, et al（eds）；WHO classification of tumours of the digestive system, 4th ed. WHO Press, Geneva, Switzerland, 2010

2）Lloyd RV, Osamura RY, Klöppel G, et al（eds）；WHO classification of tumours of endocrine organs, 4th ed. IARC Publications, 2017

3）WHO Classification of Tumours Editorial Board：WHO classification of tumours：digestive system tumours, 5th ed. IARC Publications, 2019

4）Classification of Tumours Editorial Board：WHO classification of endocrine and neuroendocrine tumours. WHO, Lyone, France, 2022

5）Rindi G, Mete O, Uccella S, et al：Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33：115-154, 2022

6）Uccella S, La Rosa S, Metovic J, et al：Genomics of high-grade neuroendocrine neoplasms：well-differentiated neuroendocrine tumor with high-grade features（G3 NET）and neuroendocrine carcinomas（NEC）of various anatomic sites. Endocr Pathol 32：192-210, 2021

7）Dasari A, Mehta K, Byers LA, et al：Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas：a SEER database analysis of 162,983 cases. Cancer 124：807-815, 2018

8）Krug S, Teupe F, Michl P, et al：Brain metastases in patients with neuroendocrine neoplasms：risk factors and outcome. BMC Cancer 19：362, 2019

9）日本神経内分泌腫瘍研究会（JNETS）膵・消化管神経内分泌腫瘍（NEN）診療ガイドライン第2版作成委員会（編）；膵・消化管神経内分泌腫瘍（NEN）診療ガイドライン2019年，第2版．金原出版，2019

10）Pavel M, Öberg K, Falconi M, et al；ESMO Guidelines Committee：Gastroenteropancreatic neuroendocrine neoplasms：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31：844-860, 2020

11）Shah MH, Goldner WS, Benson AB, et al：Neuroendocrine and adrenal tumors, Version 2.2021. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19：839-868, 2021

12）日本肺癌学会（編）；肺癌診療ガイドライン—悪性胸膜中皮腫・胸腺腫瘍含む，2022年版．金原出版，2022　https://www.haigan.gr.jp/guideline/2022/index.html

13）Takeda Y, Kobayashi N, Kessoku T, et al：Case reports：chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder. Clin J Gastroenterol 15：803-808, 2022

14）Iwamoto M, Gotoda T, Noda Y, et al：Gastric neuroendocrine carcinoma with rapid progression. Intern Med 59：1271-1276, 2020

15）Noda K, Nishiwaki Y, Kawahara M, et al：Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346：85-91, 2002

16）Sorbye H, Welin S, Langer SW, et al：Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma（WHO G3）：the NORDIC NEC study. Ann Oncol 24：152-160, 2013

17）Yamaguchi T, Machida N, Morizane C, et al：Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 105：1176-1181, 2014

18）Morizane C, Machida M, Honma Y, et al：Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system：the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol 8：1447-1455, 2022

19）Kitagawa Y, Osumi H, Shinozaki E, et al：Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract：a single cancer center retrospective study. Cancer Manag Res 11：5757-5764, 2019

20）Ando T, Hosokawa A, Yoshita H, et al：Amrubicin monotherapy for patients with platinum-refractory gastroenteropancreatic neuroendocrine carcinoma. Gastroenterol Res Pract 2015：425876, 2015

21）Hentic O, Hammel P, Couvelard A, et al：FOLFIRI regimen：an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 19：751-757, 2012

22）Hadoux J, Malka D, Planchard D, et al：Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 22：289-298, 2015

23）Welin S, Sorbye H, Sebjornsen S, et al：Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117：4617-4622, 2011

24）Vijayvergia N, Dasari A, Deng M, et al：Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms：joint analysis of two prospective, non-randomised trials. Br. J. Cancer 122：1309-1314, 2020

25）Patel SP, Othus M, Chae YK, et al：A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors（DART SWOG 1609）in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res 26：2290-2296, 2020

26）Rudin CM, Pietanza MC, Bauer TM, et al：Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer：a first-in-human, first-in-class, open-label, phase I study. Lancet Oncol 18：42-51, 2017

27）Wermke M, Felip E, Kuboki Y, et al：First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3（DLL3）/CD3 IgG-like T-cell engager in patients（pts）with DLL3-positive（DLL3＋）small-cell lung cancer（SCLC）and neuroendocrine carcinoma（NEC）. J Clin Oncol 41（suppl 16）：abstr 8502, 2023　〔https://doi.org/10.1200/JCO.2023.41.16_suppl.8502〕

28）Wermke M, Felip E, Gambardella V,et al：Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol 18：2639-2649, 2022

29）Beltran H, Dowlati A, Jain P, et al：Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life（T1/2）extended DLL3-targeting T-cell engager, in patients（pts）with neuroendocrine prostate cancer（NEPC）and other neuroendocrine neoplasms（NEN）. J Clin Oncol 42（suppl）, 2024　〔https://doi.org/10.1200/JCO.2024.42.4_suppl.121〕